Intercept Pharmaceuticals Inc EV/EBITDA
What is the EV/EBITDA of Intercept Pharmaceuticals Inc?
The EV/EBITDA of Intercept Pharmaceuticals Inc is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on NASDAQ compared to Intercept Pharmaceuticals Inc
What does Intercept Pharmaceuticals Inc do?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Companies with ev/ebitda similar to Intercept Pharmaceuticals Inc
- Balyo SA has EV/EBITDA of N/A
- Vicon has EV/EBITDA of N/A
- 908 Devices has EV/EBITDA of N/A
- CloudMD Software & Services has EV/EBITDA of N/A
- CanAlaska Uranium has EV/EBITDA of N/A
- NatureBank Asset Management has EV/EBITDA of N/A
- Intercept Pharmaceuticals Inc has EV/EBITDA of N/A
- Rincon Resources has EV/EBITDA of N/A
- Copper Search has EV/EBITDA of N/A
- A.I.S. Resources has EV/EBITDA of N/A
- UCapital24 S.p.A has EV/EBITDA of N/A
- Health Catalyst Inc has EV/EBITDA of N/A
- Syncora has EV/EBITDA of N/A